The group's principal activity is to develop and commercialize genetic diagnostic tests and medical research tools. The group develops and licenses its medical research tools, including biofusion(R) to pharmaceutical companies. The group has agreements with sheffield university, delta dental, kenna technologies, kaiser permanente for product research and development. The group's first genetic susceptibility test, pst, detects a genetic susceptibility to severe gum diseases (periodontitis). The group operates only in the United States.
